Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025


#915840

483pages

GlobalData

$ 6995

In Stock

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

In 2015, the NSCLC market in the 5EU was an estimated $1.53B. This growth is fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. Particularly, the use of PD-1 checkpoint inhibitors in first-line therapy of NSCLC is expected to take away significant sales from conventional chemotherapies that are typically used in the first line. Merck & Co.s Keytruda is the current front-runner in the first-line setting, as its already approved as a monotherapy for 50% PD-L1+ patients, and is showing benefit in combination with chemotherapy regardless of PD-L1 expression.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU NSCLC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for NSCLC.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in 5EU.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 16
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 22
3.2 Classification or Staging Systems 26
3.3 Symptoms 29
3.4 Prognosis 30
3.5 Quality of Life 32
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Diagnosis 33
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 36
4.1.3 Clinical Practice 38
4.2 France 43
4.3 Germany 44
4.4 Italy 45
4.5 Spain 46
4.6 UK 47
5 Competitive Assessment 48
5.1 Overview 48
5.2 Product Profiles - Major Brands, Epidermal Growth Factor Receptor-Targeting 50
5.2.1 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 50
5.2.2 Tarceva (erlotinib hydrochloride) 54
5.2.3 Iressa (gefitinib) 65
5.2.4 Gilotrif (afatinib) 70
5.2.5 Tagrisso (osimertinib) 79
5.2.6 Portrazza (necitumumab) 85
5.2.7 Conmana (icotinib) 91
5.3 Product Profiles - Major Brands, Anaplastic Lymphoma Kinase-Targeting 97
5.3.1 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors 97
5.3.2 Xalkori (crizotinib) 99
5.3.3 Zykadia (ceritinib) 107
5.3.4 Alecensa (alectinib) 112
5.4 Product Profiles - Major Brands, Monoclonal Antibodies 118
5.4.1 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors 118
5.4.2 Opdivo (nivolumab) 123
5.4.3 Keytruda (pembrolizumab) 130
5.4.4 Tecentriq (atezolizumab) 137
5.5 Product Profiles - Major Brands, Other 153
5.5.1 Avastin (bevacizumab) 153
5.5.2 Cyramza (ramucirumab) 159
5.5.3 Vargatef/Ofev (nintedanib) 164
5.6 Chemotherapies 168
6 Unmet Needs Assessment and Opportunity Analysis 170
6.1 Overview 170
6.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations 172
6.2.1 Unmet Need 172
6.2.2 Gap Analysis 173
6.2.3 Opportunity 174
6.3 Therapies Targeting Novel Biomarkers 175
6.3.1 Unmet Need 175
6.3.2 Gap Analysis 176
6.3.3 Opportunity 178
6.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting 179
6.4.1 Unmet Need 179
6.4.2 Gap Analysis 180
6.4.3 Opportunity 182
6.5 Alternative Testing Options for Patients with Insufficient Biopsy Material 184
6.5.1 Unmet Need 184
6.5.2 Gap Analysis 185
6.5.3 Opportunity 187
6.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance 188
6.6.1 Unmet Need 188
6.6.2 Gap Analysis 189
6.6.3 Opportunity 191
7 Pipeline Assessment 193
7.1 Overview 193
7.2 Promising Drugs in Clinical Development 195
7.2.1 Immune Checkpoint Inhibitors 198
7.2.2 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 242
7.2.3 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors 264
7.2.4 Therapeutic Cancer Vaccines 281
7.2.5 Anti-angiogenic Therapies 295
7.2.6 Avastin (bevacizumab) Biosimilars 310
7.2.7 KRAS Inhibitors 313
7.2.8 Tafinlar (dabrafenib) + Mekinist (trametinib) 323
7.2.9 Veliparib (ABT-888) 330
7.2.10 Seribantumab (MM-121) 340
7.2.11 IMMU-132 (sacituzumab govitecan) 346
7.2.12 Plinabulin (NPI-2358) 354
7.3 Promising Drugs in Early-Stage Development 360
7.3.1 Immune Checkpoint Inhibitors 361
7.3.2 Anaplastic Lymphoma Kinase Inhibitors 364
7.3.3 Neurotropic Tropomyosin-Related Kinase Inhibitors 365
7.3.4 MET inhibitors 368
7.3.5 Rearranged During Transfection Inhibitors 374
7.3.6 Human Epidermal Growth Factor 2 Inhibitors 379
7.3.7 PI3K Pathway Inhibitors 381
8 Market Outlook 384
8.1 5EU 384
8.1.1 Forecast 384
8.1.2 Key Events 386
8.1.3 Drivers and Barriers 388
9 Appendix 391
9.1 Bibliography 391
9.2 Abbreviations 437
9.3 Methodology 448
9.4 Forecasting Methodology 448
9.4.1 Diagnosed NSCLC Patients 448
9.4.2 Percent Drug-Treated Patients 449
9.4.3 Drugs Included in Each Therapeutic Class 449
9.4.4 Launch and Patent Expiry Dates 452
9.4.5 General Pricing Assumptions 454
9.4.6 Individual Drug Assumptions 456
9.4.7 Generic Erosion 470
9.4.8 Pricing of Pipeline Agents 470
9.5 Primary Research - KOLs 475
9.5.1 KOLs 475
9.6 About the Authors 479
9.6.1 Analyst 479
9.6.2 Therapy Area Director 479
9.6.3 Epidemiologist 480
9.6.4 Global Head of Healthcare 480
9.7 About GlobalData 482
9.8 Disclaimer 482

1.1 List of Tables
Table 1: Definitions Used in the AJCC Lung Cancer Staging System 27
Table 2: AJCC Staging of NSCLC 28
Table 3: Symptoms of NSCLC 30
Table 4: Prognostic Factors for NSCLC 31
Table 5: Prognosis for NSCLC Based on Initial Staging 31
Table 6: Prevalence of Brain and Bone Metastases in NSCLC 34
Table 7: Biomarker Testing Rates in Nonsquamous NSCLC 35
Table 8: Biomarker Testing Rates in Squamous NSCLC 36
Table 9: Treatment Guidelines for NSCLC 37
Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025 37
Table 11: Country Profile - France 43
Table 12: Country Profile - Germany 44
Table 13: Country Profile - Italy 45
Table 14: Country Profile - Spain 46
Table 15: Country Profile - UK 47
Table 16: Leading Treatments for NSCLC, 2016 49
Table 17: Marketed EGFR TKIs in NSCLC 51
Table 18: Product Profile - Tarceva 56
Table 19: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC 60
Table 20: Efficacy of Tarceva in Maintenance Therapy in NSCLC 61
Table 21: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC 62
Table 22: Safety of Tarceva 63
Table 23: Tarceva SWOT Analysis, 2016 64
Table 24: Product Profile - Iressa 65
Table 25: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1) 68
Table 26: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2) 68
Table 27: Safety of Iressa 69
Table 28: Iressa SWOT Analysis, 2016 70
Table 29: Product Profile - Gilotrif 72
Table 30: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC 75
Table 31: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC 76
Table 32: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Nave, Squamous NSCLC 76
Table 33: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC 77
Table 34: Safety of Gilotrif 78
Table 35: Gilotrif SWOT Analysis, 2016 79
Table 36: Product Profile - Tagrisso 80
Table 37: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC 83
Table 38: Safety of Tagrisso 84
Table 39: Tagrisso SWOT Analysis, 2016 85
Table 40: Product Profile - Portrazza 87
Table 41: Efficacy of Portrazza in First-Line, Squamous NSCLC 89
Table 42: Safety of Portrazza 90
Table 43: Portrazza SWOT Analysis, 2016 91
Table 44: Efficacy of Conmana in 2L Advanced NSCLC 94
Table 45: Efficacy of Conmana in 1L EGFR-mutant NSCLC 94
Table 46: Safety of Conmana 95
Table 47: Conmana SWOT Analysis, 2016 96
Table 48: Marketed ALK TKIs in NSCLC 97
Table 49: Product Profile - Xalkori 100
Table 50: Efficacy of Xalkori in Treatment-Nave ALK+ Metastatic NSCLC 102
Table 51: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC 103
Table 52: Safety of Xalkori in Treatment-Nave, ALK+ Metastatic NSCLC 105
Table 53: Safety of Xalkori in Previously Treated, Metastatic NSCLC 106
Table 54: Xalkori SWOT Analysis, 2016 107
Table 55: Product Profile - Zykadia 108
Table 56: Efficacy of Zykadia 110
Table 57: Safety of Zykadia 111
Table 58: Zykadia SWOT Analysis, 2016 112
Table 59: Product Profile - Alecensa 113
Table 60: Efficacy of Alecensa 115
Table 61: Efficacy of Alecensa in NSCLC patients with CNS lesions 115
Table 62: Safety of Alecensa 117
Table 63: Alecensa SWOT Analysis, 2016 118
Table 64: Marketed PD-1/PD-L1 ICIs in NSCLC 119
Table 65: Product Profile - Opdivo 124
Table 66: Efficacy of Opdivo in Metastatic Squamous NSCLC 127
Table 67: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC 128
Table 68: Safety of Opdivo 129
Table 69: Opdivo SWOT Analysis, 2016 130
Table 70: Product Profile - Keytruda 132
Table 71: Efficacy of Keytruda 135
Table 72: Safety of Keytruda 136
Table 73: Keytruda SWOT Analysis, 2016 137
Table 74: Product Profile - Tecentriq (atezolizumab) 139
Table 75: Patient Demographics in the Phase II POPLAR Trial (NCT01903993) 142
Table 76: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993) 144
Table 77: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227) 145
Table 78: Patient Demographics in the Phase II FIR Trial (NCT01846416) 146
Table 79: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416) 147
Table 80: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458) 149
Table 81: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993) 150
Table 82: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416) 151
Table 83: Tecentriq SWOT Analysis, 2016 152
Table 84: Product Profile - Avastin 154
Table 85: Efficacy of Avastin in Nonsquamous NSCLC 157
Table 86: Safety of Avastin 158
Table 87: Avastin SWOT Analysis, 2016 158
Table 88: Product Profile - Cyramza 160
Table 89: Efficacy of Cyramza 162
Table 90: Safety of Cyramza 163
Table 91: Cyramza SWOT Analysis, 2016 164
Table 92: Product Profile - Vargatef 165
Table 93: Efficacy of Vargatef in ADC NSCLC 166
Table 94: Safety of Vargatef in ADC NSCLC 167
Table 95: Vargatef SWOT Analysis, 2016 168
Table 96: Summary of Chemotherapies, 2015 169
Table 97: Unmet Need and Opportunity in NSCLC 172
Table 98: Product Profile - Yervoy (ipilimumab) 200
Table 99: Demographics in the Phase II NCT00527735 Trial 202
Table 100: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735) 204
Table 101: Demographics in the Phase I CheckMate 012 Trial (NCT01454102) 205
Table 102: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102) 206
Table 103: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735) 208
Table 104: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102) 209
Table 105: Yervoy SWOT Analysis, 2016 211
Table 106: Product Profile - Avelumab (MSB-0010718C) 214
Table 107: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004) 216
Table 108: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004) 217
Table 109: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC 218
Table 110: Demographics in the Treatment-Nave NSCLC Cohort in the Phase I Trial (NCT01772004) 219
Table 111: Efficacy of Avelumab in Treatment-Nave NSCLC 220
Table 112: Unconfirmed ORR According to PD-L1 Expression in Treatment-Nave NSCLC 221
Table 113: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004) 222
Table 114: Safety of Avelumab in Treatment-Nave NSCLC (NCT01772004) 223
Table 115: Avelumab SWOT Analysis, 2016 225
Table 116: Product Profile - Durvalumab (MEDI4736) 227
Table 117: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial 230
Table 118: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial 231
Table 119: Baseline Characteristics of Patients With Treatment-Nave NSCLC in the Phase I/II 232
Table 120: Efficacy of Durvalumab in Treatment-Nave NSCLC 233
Table 121: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial 234
Table 122: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial 236
Table 123: Safety of Durvalumab in the Phase I/II Trial (NCT01693562) 237
Table 124: Safety of Durvalumab in Treatment-Nave NSCLC 238
Table 125: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial 239
Table 126: Durvalumab SWOT Analysis, 2016 241
Table 127: Product Profile - Naquotinib Mesylate (ASP8273) 245
Table 128: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials 246
Table 129: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients 247
Table 130: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients 248
Table 131: Naquotinib SWOT Analysis, 2016 249
Table 132: Product Profile - Olmutinib (BI 1482694; HM61713) 250
Table 133: Demographics in the Phase I/II NCT01588145 Trial 252
Table 134: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial 253
Table 135: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial 254
Table 136: Olmutinib SWOT Analysis, 2016 255
Table 137: Product Profile - Dacomitinib 257
Table 138: Demographics in the Phase II NCT00818441 Trial 259
Table 139: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial 260
Table 140: Safety of Dacomitinib in Phase II NCT00818441 Trial 262
Table 141: Dacomitinib SWOT Analysis, 2016 263
Table 142: Product Profile - Ensartinib 266
Table 143: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534) 267
Table 144: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534) 268
Table 145: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial 269
Table 146: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534) 270
Table 147: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534) 271
Table 148: Ensartinib SWOT Analysis, 2016 272
Table 149: Product Profile - Brigatinib 274
Table 150: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573) 276
Table 151: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573) 277
Table 152: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases 278
Table 153: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573) 279
Table 154: Brigatinib SWOT Analysis, 2016 280
Table 155: Product Profile - CimaVax-EGF 283
Table 156: Demographics in the Phase III trial of the CimaVax-EGF in Cuba 285
Table 157: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba 286
Table 158: Safety of the CimaVax-EGF in the Phase III Trial in Cuba 287
Table 159: CimaVax-EGF SWOT Analysis, 2016 289
Table 160: Product Profile - Tedopi 291
Table 161: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC 292
Table 162: Efficacy of Tedopi in Advanced NSCLC 293
Table 163: Tedopi SWOT Analysis, 2016 295
Table 164: Product Profile - Anlotinib 297
Table 165: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial 298
Table 166: Anlotinib SWOT Analysis, 2016 299
Table 167: Product Profile - Aitan 301
Table 168: Efficacy of Aitan in Pretreated Nonsquamous NSCLC 302
Table 169: Aitan SWOT Analysis, 2016 303
Table 170: Product Profile - Fruquintinib 305
Table 171: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib 306
Table 172: Efficacy of Fruquintinib in Advanced Solid Tumors 307
Table 173: Safety of Fruquintinib in Advanced Solid Tumors 308
Table 174: Fruquintinib SWOT Analysis, 2016 309
Table 175: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003) 312
Table 176: Product Profile - Abemaciclib 316
Table 177: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016) 318
Table 178: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636) 319
Table 179: Safety of Abemaciclib in Combination with Multiple Single Agents 320
Table 180: Abemaciclib SWOT Analysis, 2016 322
Table 181: Product Profile - Tafinlar + Mekinist 324
Table 182: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634) 326
Table 183: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC 327
Table 184: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC 328
Table 185: Tafinlar + Mekinist SWOT Analysis, 2016 330
Table 186: Product Profile - Veliparib 332
Table 187: Demographics in the Phase II NCT01560104 Trial 334
Table 188: Efficacy of VCP in Advanced NSCLC (NCT01560104) 335
Table 189: Efficacy of VCP by Smoking Status (NCT01560104) 336
Table 190: Safety of VCP in Advanced NSCLC (NCT01560104) 337
Table 191: Veliparib SWOT Analysis, 2016 339
Table 192: Product Profile - Seribantumab (MM-121) 341
Table 193: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in 342
Table 194: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC 343
Table 195: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC 344
Table 196: MM-121 SWOT Analysis, 2016 345
Table 197: Product Profile - Sacituzumab govitecan (IMMU-132) 347
Table 198: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552) 349
Table 199: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552) 350
Table 200: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor 351
Table 201: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552) 352
Table 202: IMMU-132 SWOT Analysis, 2016 353
Table 203: Product Profile - Plinabulin 355
Table 204: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110) 357
Table 205: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110) 357
Table 206: Plinabulin SWOT Analysis, 2016 359
Table 207: Early-Stage Clinical Development in NSCLC 361
Table 208: MET Status in the Phase II (NCT01610336) Trial 370
Table 209: Efficacy of Capmatinib + Iressa in MET+ NSCLC 371
Table 210: Demographics in the Phase II LURET Study 376
Table 211: Efficacy of Caprelsa in RET+ NSCLC 376
Table 212: Demographics in the Stage I of the Phase II NCT01639508 Trial 378
Table 213: Efficacy of Cometriq in RET+ NSCLC 379
Table 214: Key Events Impacting Sales for NSCLC in the 5EU, 2016 386
Table 215: NSCLC -Drivers and Barriers in the 5EU, 20152025 388
Table 216: Key Launch Dates - Part I 452
Table 217: Key Launch Dates - Part II 453
Table 218: Key Patent Expiries 454
Table 219 Average Body Weight and Surface Area Across the 8MM 455
Table 216: Average Cost of Therapy of Alimta in the 8MM 457
Table 217: Average Cost of Therapy of Alecensa in the 8MM 458
Table 218: Average Cost of Therapy of Avastin 459
Table 219: Average Cost of Therapy of Cyramza 459
Table 220: Average Cost of Therapy of Gilotrif 460
Table 221: Average Cost of Therapy of Iressa 461
Table 222: Average Cost of Therapy of Portrazza 462
Table 223: Average Cost of Therapy of Tagrisso 463
Table 224: Average Cost of Therapy of Tarceva 464
Table 225: Average Cost of Therapy of Vargatef 464
Table 226: Average Cost of Therapy of Xalkori 465
Table 227: Average Cost of Therapy of Zykadia 466
Table 228: Average Cost of Therapy of Keytruda 467
Table 229: Average Cost of Therapy of Opdivo 468
Table 230: Average Cost of Therapy of Tecentriq 469
Table 231: Average Cost of Therapy of Conmana 470
Table 232: High-Prescribing Physicians Surveyed by Country 478

1.2 List of Figures
Figure 1: Disease Management Flowchart for nonsquamous NSCLC 39
Figure 2: Disease Management Flowchart for squamous NSCLC 40
Figure 3: Disease Management Flowchart for EGFR+ NSCLC 41
Figure 4: Disease Management Flowchart for ALK+ NSCLC 42
Figure 5: Tarcevas Phase III Development in NSCLC 57
Figure 6: Iressas Phase II Development in NSCLC 66
Figure 7: Gilotrifs Phase III Development in NSCLC 74
Figure 8: Tagrissos Phase III Development in NSCLC 81
Figure 9: Portrazzas Phase II Development in NSCLC 88
Figure 10: Conmanas Phase III Development in NSCLC 93
Figure 11: Xalkoris Development in NSCLC 101
Figure 12: Zykadias Development in NSCLC 109
Figure 13: Alecensas Development in NSCLC 114
Figure 14: Opdivos Development in NSCLC 126
Figure 15: Keytrudas Phase III Development in NSCLC 134
Figure 16: Tecentriqs Clincal Development in NSCLC 141
Figure 17: Avastins Phase III Development in NSCLC 155
Figure 18: Cyramzas Phase III Development in NSCLC 161
Figure 19: Vargatefs Phase II Development in NSCLC 166
Figure 20: NSCLC - Phase II/III Pipeline, 2016, Part I 195
Figure 21: NSCLC - Phase II/III Pipeline, 2016, Part II 196
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025 197
Figure 23: Yervoys Clinical Development in NSCLC 201
Figure 24: Clinical and Commercial Positioning of Yervoy 210
Figure 25: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025 212
Figure 26: Avelumabs Development in NSCLC 215
Figure 27: Clinical and Commercial Positioning of Avelumab 224
Figure 28: Durvalumabs Clinical Development in NSCLC 228
Figure 29: Clinical and Commercial Positioning of Durvalumab 240
Figure 30: Naquotinibs Clincal Development in NSCLC 245
Figure 31: Clinical and Commercial Positioning of Naquotinib 248
Figure 32: Olmutinibs Clincal Development in NSCLC 251
Figure 33: Clinical and Commercial Positioning of Olmutinib 254
Figure 34: Dacomitinibs Clinical Development in NSCLC 257
Figure 35: Clinical and Commercial Positioning of Dacomitinib 263
Figure 36: Ensartinibs Clinical Development in NSCLC 266
Figure 37: Clinical and Commercial Positioning of Ensartinib 271
Figure 38: Brigatinibs Clinical Development in NSCLC 275
Figure 39: Clinical and Commercial Positioning of Brigatinib 280
Figure 40: CimaVax-EGFs Clinical Development in NSCLC 284
Figure 41: Clinical and Commercial Positioning of CimaVax-EGF 288
Figure 42: Tedopis Clinical Development in NSCLC 291
Figure 43: Clinical and Commercial Positioning of Tedopi 294
Figure 44: Anlotinibs Clinical Development in NSCLC 297
Figure 45: Clinical and Commercial Positioning of Anlotinib 299
Figure 46: Aitans Clinical Development in NSCLC 301
Figure 47: Clinical and Commercial Positioning of Aitan 303
Figure 48: Fruquintinibs Clinical Development in NSCLC 305
Figure 49: Clinical and Commercial Positioning of Fruquintinib 309
Figure 50: Clinical Development of Avastin Biosimilars in NSCLC 311
Figure 51: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025 313
Figure 52: Abemaciclibs Clinical Development in NSCLC 317
Figure 53: Clinical and Commercial Positioning of Abemaciclib 321
Figure 54: Tafinlar + Mekinists Clinical Development in NSCLC 325
Figure 55: Clinical and Commercial Positioning of Tafinlar + Mekinist 329
Figure 56: Veliparibs Clinical Development in NSCLC 333
Figure 57: Clinical and Commercial Positioning of Veliparib 338
Figure 58: MM-121s Clinical Development in NSCLC 341
Figure 59: Clinical and Commercial Positioning of MM-121 345
Figure 60: IMMU-132s Clinical Development in NSCLC 348
Figure 61: Clinical and Commercial Positioning of IMMU-132 353
Figure 62: Plinabulins Clinical Development in NSCLC 356
Figure 63: Clinical and Commercial Positioning of Plinabulin 358
Figure 64: Sales for NSCLC in the 5EU by Drug Class, 2015-2025 385